[Recent advances in digestive oncology (pancreas excluded)].
The present manuscript focus on new data regarding gastro-intestinal (GI) tumors (pancreas excluded). Two mains issues are discussed: advances in terms of the molecular basis of GI oncogenesis, and the data on molecular targeted agents for which the cost/efficacity balance needs to be addressed.
Elias
Dominique
D
Département de chirurgie digestive carcinologique, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif Cedex. elias@igr.fr
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic; D003362:Cost-Benefit Analysis; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000235:genetics / Q000503:physiopathology*; D006801:Humans; D006979:Hyperthermia, Induced